Antibe Therapeutics Unveils Lead Indication for Second Pipeline Drug
Antibe Therapeutics announced the lead indication for its second pipeline drug, ATB-352, a potent and non-addictive analgesic for the treatment of severe pain.
Previous
Previous
FACIT Portfolio Announces $750M Follow-On Financing
Next
Next